Latest Expert Opinions

Signal
Opinion
Expert
SELL
SELL
December 7, 2018
They have fallen on hard times. They have deals on the table, but no guarantees, and the margins are thin in this business. This trades at a cheap multiple though at 5x forward earnings and 2x cash flow. They have to close deals and get wider margins. A tax-loss sell.
Show full opinionHide full opinion
They have fallen on hard times. They have deals on the table, but no guarantees, and the margins are thin in this business. This trades at a cheap multiple though at 5x forward earnings and 2x cash flow. They have to close deals and get wider margins. A tax-loss sell.
DON'T BUY
DON'T BUY
December 7, 2018
Their last quarter wasn't great; there was some positive news in their pharma pipeline. They sold assets from BASF to reduce net debt, which is now at Euros 36.5 billion. The debt-to-cash flow is still high, so they have a low credit rating. Their chemical side isn't growing. EPS are down 18%, which pressured the stock. JNJ has a better phrama pipeline and credit rating.
Show full opinionHide full opinion
Bayer AG (BAYRY-OTC)
December 7, 2018
Their last quarter wasn't great; there was some positive news in their pharma pipeline. They sold assets from BASF to reduce net debt, which is now at Euros 36.5 billion. The debt-to-cash flow is still high, so they have a low credit rating. Their chemical side isn't growing. EPS are down 18%, which pressured the stock. JNJ has a better phrama pipeline and credit rating.
DON'T BUY
DON'T BUY
December 7, 2018
Corruption in Asia has triggered a sell-off. He prefers TD, and owns no US banks. (TD operates in the US.) If they can't shake off these corruption charges, then GS will be in the penalty box for a while
Show full opinionHide full opinion
Goldman Sachs (GS-N)
December 7, 2018
Corruption in Asia has triggered a sell-off. He prefers TD, and owns no US banks. (TD operates in the US.) If they can't shake off these corruption charges, then GS will be in the penalty box for a while
COMMENT
COMMENT
December 7, 2018
Been stuck in a trading range the past five years: Buy or wait? In 2008, FFH made a lot of money shorting the market, and in the past year he's taken off those shorts and sold all his bonds till he's sitting in cash. Not a good strategy. The combined ratios in their insurance business is high vs. peers. Prem Watsa has been successful buying bad insurance companies and turning them around, but has been successful only sometimes. That said, he likes the future of FFH--as they allocate their cash.
Show full opinionHide full opinion
Fairfax Financial (FFH-T)
December 7, 2018
Been stuck in a trading range the past five years: Buy or wait? In 2008, FFH made a lot of money shorting the market, and in the past year he's taken off those shorts and sold all his bonds till he's sitting in cash. Not a good strategy. The combined ratios in their insurance business is high vs. peers. Prem Watsa has been successful buying bad insurance companies and turning them around, but has been successful only sometimes. That said, he likes the future of FFH--as they allocate their cash.
SELL
SELL
December 7, 2018
Tax-loss sell it. Most recently, they are recalling power-generation units around the world, which will further drag down revenues. 20 years ago, this was a quality company. No longer.
Show full opinionHide full opinion
General Electric (GE-N)
December 7, 2018
Tax-loss sell it. Most recently, they are recalling power-generation units around the world, which will further drag down revenues. 20 years ago, this was a quality company. No longer.
BUY
BUY
December 7, 2018
TEVA vs. GSK Teva is in turnaround with a lot of debt to pay off. They need a boast from their future products moving forward. GSK is higher quality with higher credit rating, and lack Teva's debt woes. GSK is the better bet.
Show full opinionHide full opinion
TEVA vs. GSK Teva is in turnaround with a lot of debt to pay off. They need a boast from their future products moving forward. GSK is higher quality with higher credit rating, and lack Teva's debt woes. GSK is the better bet.
DON'T BUY
DON'T BUY
December 7, 2018
TEVA vs. GSK Teva is in turnaround with a lot of debt to pay off. They need a boast from their future products moving forward. GSK is higher quality with higher credit rating, and lack Teva's debt woes. GSK is the better bet.
Show full opinionHide full opinion
TEVA vs. GSK Teva is in turnaround with a lot of debt to pay off. They need a boast from their future products moving forward. GSK is higher quality with higher credit rating, and lack Teva's debt woes. GSK is the better bet.